Development of dds using hollow bio-nanoparticles and their commercialization

Akihiko Kondo, Shun ichi Kuroda, Katsuyuki Tanizawa, Masaharu Seno, Masakazu Ueda

Research output: Contribution to journalArticle

Abstract

We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

Original languageEnglish
Pages (from-to)435-443
Number of pages9
JournalDrug Delivery System
Volume21
Issue number4
DOIs
Publication statusPublished - 2006

Fingerprint

Viral DNA
Particle Size
Nanoparticles
Hepatocytes
Yeasts
Ligands
Peptides
Liver
Pharmaceutical Preparations
Genes
Proteins
protein S precursor

Keywords

  • gene therapy
  • hepatitis B virus
  • nanoparticle
  • pinpoint drug delivery
  • targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Development of dds using hollow bio-nanoparticles and their commercialization. / Kondo, Akihiko; Kuroda, Shun ichi; Tanizawa, Katsuyuki; Seno, Masaharu; Ueda, Masakazu.

In: Drug Delivery System, Vol. 21, No. 4, 2006, p. 435-443.

Research output: Contribution to journalArticle

Kondo, Akihiko ; Kuroda, Shun ichi ; Tanizawa, Katsuyuki ; Seno, Masaharu ; Ueda, Masakazu. / Development of dds using hollow bio-nanoparticles and their commercialization. In: Drug Delivery System. 2006 ; Vol. 21, No. 4. pp. 435-443.
@article{4de0888085364d4ea10c1d006307ba9d,
title = "Development of dds using hollow bio-nanoparticles and their commercialization",
abstract = "We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.",
keywords = "gene therapy, hepatitis B virus, nanoparticle, pinpoint drug delivery, targeting",
author = "Akihiko Kondo and Kuroda, {Shun ichi} and Katsuyuki Tanizawa and Masaharu Seno and Masakazu Ueda",
year = "2006",
doi = "10.2745/dds.21.435",
language = "English",
volume = "21",
pages = "435--443",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "4",

}

TY - JOUR

T1 - Development of dds using hollow bio-nanoparticles and their commercialization

AU - Kondo, Akihiko

AU - Kuroda, Shun ichi

AU - Tanizawa, Katsuyuki

AU - Seno, Masaharu

AU - Ueda, Masakazu

PY - 2006

Y1 - 2006

N2 - We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

AB - We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

KW - gene therapy

KW - hepatitis B virus

KW - nanoparticle

KW - pinpoint drug delivery

KW - targeting

UR - http://www.scopus.com/inward/record.url?scp=85024471530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024471530&partnerID=8YFLogxK

U2 - 10.2745/dds.21.435

DO - 10.2745/dds.21.435

M3 - Article

VL - 21

SP - 435

EP - 443

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 4

ER -